Saniona AB Cash Flow Conversion Efficiency

Latest as of December 2025: -0.125x

Saniona AB cash flow conversion efficiency. Based on the latest financial reports, Saniona AB (SANION) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-79.51 Million ≈ $-8.56 Million USD) by net assets (Skr635.16 Million ≈ $68.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Saniona AB (2013–2025)

Cash flow conversion efficiency of Saniona AB from 2013 to 2025. This chart illustrates how Saniona AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Saniona AB stock price today for real-time trading data and today's change.

Saniona AB Cash Flow Conversion Ratio Explained

Saniona AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Saniona AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Saniona AB ranked by their cash flow conversion efficiency. Also see Saniona AB (SANION) market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
0.053x
Mayfair Gold Corp
V:MFG
-0.176x
Tachan Securities Co Ltd
TWO:6020
-0.043x
Wellgistics Health, Inc. Common Stock
NASDAQ:WGRX
0.227x
Deep Fission, Inc. Common Stock
NASDAQ:FISN
-0.288x
Ordinary Fully Paid Deferred Settlement
AU:BTRDA
N/A
Orvana Minerals Corp.
TO:ORV
0.525x
Intellego Technologies AB
ST:INT
0.791x

Annual Cash Flow Conversion Efficiency for Saniona AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Saniona AB from 2013 to 2025. Review SANION cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr635.16 Million
≈ $68.35 Million
Skr273.86 Million
≈ $29.47 Million
0.431x -59.89%
2024-12-31 Skr231.82 Million
≈ $24.95 Million
Skr249.20 Million
≈ $26.82 Million
1.075x -72.43%
2023-12-31 Skr-21.94 Million
≈ $-2.36 Million
Skr-85.53 Million
≈ $-9.20 Million
3.898x +172.98%
2022-12-31 Skr52.71 Million
≈ $5.67 Million
Skr-281.54 Million
≈ $-30.30 Million
-5.341x -336.56%
2021-12-31 Skr282.00 Million
≈ $30.35 Million
Skr-345.04 Million
≈ $-37.13 Million
-1.224x -322.61%
2020-12-31 Skr603.46 Million
≈ $64.94 Million
Skr-174.71 Million
≈ $-18.80 Million
-0.290x +82.82%
2019-12-31 Skr58.44 Million
≈ $6.29 Million
Skr-98.47 Million
≈ $-10.60 Million
-1.685x -190.08%
2018-12-31 Skr39.46 Million
≈ $4.25 Million
Skr-22.92 Million
≈ $-2.47 Million
-0.581x +61.88%
2017-12-31 Skr37.63 Million
≈ $4.05 Million
Skr-57.34 Million
≈ $-6.17 Million
-1.524x -1139.50%
2016-12-31 Skr54.25 Million
≈ $5.84 Million
Skr7.95 Million
≈ $855.87K
0.147x +126.93%
2015-12-31 Skr52.94 Million
≈ $5.70 Million
Skr-28.82 Million
≈ $-3.10 Million
-0.544x +39.93%
2014-12-31 Skr8.78 Million
≈ $944.98K
Skr-7.96 Million
≈ $-856.41K
-0.906x +86.10%
2013-12-31 Skr575.00K
≈ $61.88K
Skr-3.75 Million
≈ $-403.34K
-6.518x --

About Saniona AB

ST:SANION Sweden Biotechnology
Market Cap
$157.31 Million
Skr1.46 Billion SEK
Market Cap Rank
#17281 Global
#294 in Sweden
Share Price
Skr10.59
Change (1 day)
+0.38%
52-Week Range
Skr9.03 - Skr27.50
All Time High
Skr52.03
About

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more